SMT202200228T1 - Trattamento per la malattia di parkinson - Google Patents

Trattamento per la malattia di parkinson

Info

Publication number
SMT202200228T1
SMT202200228T1 SM20220228T SMT202200228T SMT202200228T1 SM T202200228 T1 SMT202200228 T1 SM T202200228T1 SM 20220228 T SM20220228 T SM 20220228T SM T202200228 T SMT202200228 T SM T202200228T SM T202200228 T1 SMT202200228 T1 SM T202200228T1
Authority
SM
San Marino
Prior art keywords
parkinson
disease
treatment
Prior art date
Application number
SM20220228T
Other languages
English (en)
Italian (it)
Inventor
Trinadha Rao Chitturi
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of SMT202200228T1 publication Critical patent/SMT202200228T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20220228T 2016-06-02 2017-06-02 Trattamento per la malattia di parkinson SMT202200228T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
SMT202200228T1 true SMT202200228T1 (it) 2022-07-21

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220228T SMT202200228T1 (it) 2016-06-02 2017-06-02 Trattamento per la malattia di parkinson

Country Status (27)

Country Link
US (4) US10849887B2 (OSRAM)
EP (2) EP3463351B1 (OSRAM)
JP (1) JP6974357B2 (OSRAM)
KR (1) KR102508288B1 (OSRAM)
CN (1) CN109475539B (OSRAM)
AU (1) AU2017273415B2 (OSRAM)
CA (1) CA3024976A1 (OSRAM)
CL (1) CL2018003431A1 (OSRAM)
CY (1) CY1125285T1 (OSRAM)
DK (1) DK3463351T3 (OSRAM)
ES (1) ES2914782T3 (OSRAM)
HR (1) HRP20220683T1 (OSRAM)
HU (1) HUE059387T2 (OSRAM)
IL (1) IL263188B (OSRAM)
LT (1) LT3463351T (OSRAM)
MX (1) MX385276B (OSRAM)
MY (1) MY193754A (OSRAM)
NZ (1) NZ748592A (OSRAM)
PH (1) PH12018502457B1 (OSRAM)
PL (1) PL3463351T3 (OSRAM)
PT (1) PT3463351T (OSRAM)
RS (1) RS63243B1 (OSRAM)
SG (1) SG11201810294QA (OSRAM)
SI (1) SI3463351T1 (OSRAM)
SM (1) SMT202200228T1 (OSRAM)
UA (1) UA123018C2 (OSRAM)
WO (1) WO2017208267A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
HUE059387T2 (hu) * 2016-06-02 2022-11-28 Sun Pharma Advanced Res Co Ltd Parkinson-kór kezelése
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
AU2019385480B2 (en) 2018-11-20 2025-04-24 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
AU2020292703A1 (en) 2019-06-11 2022-01-27 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
CA3185939A1 (en) 2020-07-31 2022-02-03 Nitin Krishnaji Damle N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103502217B (zh) * 2011-01-21 2015-11-25 太阳医药高级研究有限公司 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
CA2985161A1 (en) 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
HUE059387T2 (hu) * 2016-06-02 2022-11-28 Sun Pharma Advanced Res Co Ltd Parkinson-kór kezelése

Also Published As

Publication number Publication date
UA123018C2 (uk) 2021-02-03
CN109475539A (zh) 2019-03-15
WO2017208267A1 (en) 2017-12-07
EP4085912A1 (en) 2022-11-09
CL2018003431A1 (es) 2019-05-10
HUE059387T2 (hu) 2022-11-28
US20210015805A1 (en) 2021-01-21
HRP20220683T1 (hr) 2022-07-08
KR20190015257A (ko) 2019-02-13
US11813252B2 (en) 2023-11-14
MY193754A (en) 2022-10-27
US20190275017A1 (en) 2019-09-12
US20220273632A1 (en) 2022-09-01
PH12018502457A1 (en) 2019-10-21
BR112018074439A2 (pt) 2019-03-06
MX2018014944A (es) 2019-03-07
PL3463351T3 (pl) 2022-06-20
EP3463351A1 (en) 2019-04-10
CY1125285T1 (el) 2025-03-28
SG11201810294QA (en) 2018-12-28
SI3463351T1 (sl) 2022-07-29
PH12018502457B1 (en) 2022-01-12
US11583522B2 (en) 2023-02-21
US10849887B2 (en) 2020-12-01
US20240066014A1 (en) 2024-02-29
IL263188B (en) 2021-08-31
JP2019520344A (ja) 2019-07-18
EP3463351B1 (en) 2022-04-27
KR102508288B1 (ko) 2023-03-09
MX385276B (es) 2025-03-18
AU2017273415B2 (en) 2023-01-19
JP6974357B2 (ja) 2021-12-01
AU2017273415A1 (en) 2018-12-06
NZ748592A (en) 2025-11-28
DK3463351T3 (da) 2022-06-07
PT3463351T (pt) 2022-06-02
IL263188A (en) 2018-12-31
LT3463351T (lt) 2022-06-10
CN109475539B (zh) 2021-12-28
CA3024976A1 (en) 2017-12-07
ES2914782T3 (es) 2022-06-16
RS63243B1 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
IL285722A (en) Methods for treating Alzheimer's disease
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
IL263188B (en) Treatment for Parkinson's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL247085A0 (en) Methods for treating Alzheimer's disease
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
IL246999B (en) Methods for treating Alzheimer's disease
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
EP3244897A4 (en) Methods for treating alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK40014282A (en) Methods for treating parkinson's disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201414038D0 (en) Alzheimer's disease